Diagnostic Value of the PEI-Q and Pancreatic Ultrasound for Identifying Reduced Pancreatic Exocrine Function in Early Type 2 Diabetes
- 1Department of Internal Diseases No 1, West Kazakhstan Marat Ospanov Medical University, Aktobe 030000, Kazakhstan
- 2Administrative and Management Personnel (AMP), West Kazakhstan Marat Ospanov Medical University, Aktobe 030000, Kazakhstan
- 3Department of Endocrinology, Nicolae Testemitanu State University of Medicine and Pharmacy, MD-2012 Chisinau, Moldova
Abstract
Background/Objectives: Pancreatic symptoms and structural abnormalities do not necessarily correspond to reduced exocrine function in type 2 diabetes mellitus (T2DM). We aimed to estimate the frequency of reduced fecal elastase-1 (FE-1) and examine its associations with gastrointestinal symptom burden and pancreatic ultrasound findings. Methods: This cross-sectional study included 251 Kazakh adults with T2DM of ≤5 years’ duration not receiving insulin therapy. FE-1 < 200 μg/g was classified as reduced. Symptoms were assessed using the Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q). Model 1 included pancreatic dimensions, splenic vein diameter, and Wirsung duct dilatation; Model 2 included splenic vein diameter, duct dilatation, and PEI-Q score; Model 3 additionally adjusted for age, sex, BMI, and current smoking. Discrimination was assessed using ROC analysis, with paired DeLong comparisons and Holm adjustment. Results: Reduced FE-1 was identified in 59 participants (23.5%) and was associated with higher PEI-Q scores, smaller pancreatic dimensions, and more frequent Wirsung duct dilatation. In Model 3, duct dilatation (adjusted OR 5.388, 95% CI 2.346–12.376) and PEI-Q score (adjusted OR 2.089, 95% CI 1.043–4.187) were independently associated with reduced FE-1. PEI-Q alone showed limited discrimination (AUC 0.583); AUCs for Models 1, 2, and 3 were 0.771, 0.697, and 0.726, respectively. Model 2 did not significantly outperform Model 1, and Model 3 did not significantly outperform Model 2. Conclusions: Reduced FE-1 was identified in 23.5% of participants and was associated with symptom burden and selected ultrasound findings. PEI-Q alone showed limited discrimination, whereas models incorporating ultrasound variables showed higher AUCs. Neither PEI-Q nor pancreatic ultrasound can replace FE-1 measurement; external validation is required before clinical application.
Related
- Serum Bile Acid Concentrations in Dogs with Exocrine Pancreatic Insufficiency
- Diagnostic Performance and Safety of Endoscopic Ultrasound-Guided Fine-Needle Biopsy (EUS-FNB) Under Conscious Sedation for Small Solid Pancreatic Lesions (<20 mm): A Retrospective Cohort Study
- Macroscopic Tissue Integrity and Histological Diagnostic Yield During Endoscopic Ultrasound-Guided Tissue Acquisition for Solid Pancreatic Lesions
- Integration of computed tomography and endoscopic findings in identifying pseudoaneurysm rupture associated with duodenal penetration by pancreatic head cancer: A case report
- Endoscopic Ultrasound-Guided Radiofrequency Ablation for an Adrenocorticotropic Hormone-Secreting Pancreatic Neuroendocrine Tumor on Antiplatelet Therapy.
BibTeX
@article{bazargaliyev2026diagnostic,
title = {{Diagnostic Value of the PEI-Q and Pancreatic Ultrasound for Identifying Reduced Pancreatic Exocrine Function in Early Type 2 Diabetes}},
author = {Yerlan Bazargaliyev and Talgar Abilov and Mengtay Makashova and Khatimya Kudabayeva and Lorina Vudu},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15208157},
url = {https://www.mdpi.com/2077-0383/15/20/8157},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Diagnostic Value of the PEI-Q and Pancreatic Ultrasound for Identifying Reduced Pancreatic Exocrine Function in Early Type 2 Diabetes
AU - Yerlan Bazargaliyev
AU - Talgar Abilov
AU - Mengtay Makashova
AU - Khatimya Kudabayeva
AU - Lorina Vudu
PY - 2026
DA - 2026/10/01
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15208157
UR - https://www.mdpi.com/2077-0383/15/20/8157
AB - Background/Objectives: Pancreatic symptoms and structural abnormalities do not necessarily correspond to reduced exocrine function in type 2 diabetes mellitus (T2DM). We aimed to estimate the frequency of reduced fecal elastase-1 (FE-1) and examine its associations with gastrointestinal symptom burden and pancreatic ultrasound findings. Methods: This cross-sectional study included 251 Kazakh adults with T2DM of ≤5 years’ duration not receiving insulin therapy. FE-1 < 200 μg/g was classified as reduced. Symptoms were assessed using the Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q). Model 1 included pancreatic dimensions, splenic vein diameter, and Wirsung duct dilatation; Model 2 included splenic vein diameter, duct dilatation, and PEI-Q score; Model 3 additionally adjusted for age, sex, BMI, and current smoking. Discrimination was assessed using ROC analysis, with paired DeLong comparisons and Holm adjustment. Results: Reduced FE-1 was identified in 59 participants (23.5%) and was associated with higher PEI-Q scores, smaller pancreatic dimensions, and more frequent Wirsung duct dilatation. In Model 3, duct dilatation (adjusted OR 5.388, 95% CI 2.346–12.376) and PEI-Q score (adjusted OR 2.089, 95% CI 1.043–4.187) were independently associated with reduced FE-1. PEI-Q alone showed limited discrimination (AUC 0.583); AUCs for Models 1, 2, and 3 were 0.771, 0.697, and 0.726, respectively. Model 2 did not significantly outperform Model 1, and Model 3 did not significantly outperform Model 2. Conclusions: Reduced FE-1 was identified in 23.5% of participants and was associated with symptom burden and selected ultrasound findings. PEI-Q alone showed limited discrimination, whereas models incorporating ultrasound variables showed higher AUCs. Neither PEI-Q nor pancreatic ultrasound can replace FE-1 measurement; external validation is required before clinical application.
SN - 2077-0383
ER -